Q-omics provides the consensus-scored SKINT1L profile across patient tissues and cancer cell-line models. SKINT1L expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SKINT1L is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, SKINT1L RNA expression shows 15,889 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where SKINT1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SKINT1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SKINT1L survival associations across molecular data types. SKINT1L RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SKINT1L RNA expression–survival associations across cancer types. High SKINT1L expression shows unfavorable associations in KIRC, LGG and LUSC, but favorable associations in BLCA, READ and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SKINT1L RNA expression.
This table summarizes SKINT1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SKINT1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SKINT1L shows lower tumor expression in BRCA, LUAD and LUSC and higher tumor expression in KIRC, CHOL and LIHC. The KIRC box plot shows higher SKINT1L RNA expression in tumor versus normal tissue (log2 FC = +0.118, t-test p < 0.001).
This table shows molecular features associated with SKINT1L in patient tissues and cancer cell lines. In patient samples, SKINT1L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
